Skip to content

Effect of Antibiotics on Enteric Neurons and Glia

Effect of Antibiotics on Submucosal Enteric Neurons and Glia in the Lower Gastrointestinal

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05834036
Enrollment
10
Registered
2023-04-28
Start date
2023-06-23
Completion date
2023-11-09
Last updated
2026-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Enterocolitis

Keywords

Glia, Enteric Neurons

Brief summary

The interactions between bacteria and their products with the intestinal tissue are important for maintaining a healthy and balanced system. Alterations in gut bacteria communities have been associated with various human pathologies. The investigators have found that mice treated with short and long-term antibiotics exhibit a transient yet profound loss of neurons in the more superficial submucosal and deeper muscularis plexi in the intestine accompanied by slow motility. Glia cells also depend on microbiota for their maintenance. In humans, antibiotic use has been associated with disorders of gut-brain interactions (DGBI) such as irritable bowel syndrome however whether there are changes in the enteric neurons and glia cells remain unknown. Therefore, the investigators propose to further characterize the neurons and glia populations in the human distal colon after a single antibiotic course. This study will reveal glia and neuronal subtypes that are susceptible to changes in the bacteria populations and depend on microbial products for their maintenance. These findings will guide future DGBI studies to ascertain the physiological effects that such loss has on intestinal healthy balance.

Detailed description

The enteric nervous system (ENS) has been recognized as the "second brain" as it can regulate enteric physiology without central nervous system input. Similar to the central nervous system, it is composed of multiple neuron populations whose main functions are gut motility, secretion, and absorption. In addition to the neurons, the ENS contains glia cells whose main role is neuroprotection but also contribute to normal gut motility. Several studies have demonstrated that the microbiota and the ENS have an intimate relationship that begins in utero, and it is critical for its normal development. Neurons can recognize bacteria and their products. Several investigators have shown neuronal loss after enteric infections and antibiotic (Ampicillin) treatment in the muscularis layer, that results in delayed transit time in animal models. Hence, communication between the microbiota and the ENS is important to maintain normal gut motility. Disorders of Gut-Brain Interactions (DGBIs) are quite common, among these are Irritable Bowel Syndrome (IBS) defined by Rome IV criteria as abdominal pain associated with a change in consistency and frequency of bowel movements and the constipation predominant subtype (less than 3 bowel movements per week) is the most prevalent, which is also the most common motility disorder that mouse models of infection and antibiotics treatment exhibit. IBS has been associated with dysbiosis and a recent study demonstrated that antibiotic use immediately before or after screening colonoscopy increased the risk of developing IBS. In addition, dysfunction of submucosal neurons in IBS has been previously reported but whether there are changes in neuron numbers or neuron characteristics has not been explored. While there have been prospective studies that have explored the effects of antibiotics in patients treated for Helicobacter Pylori, there have been other investigators who have focused on the long term effects of antibiotics in healthy volunteers. Therefore, similar to animal models, investigators propose that humans experience a profound and transient loss/alteration of neurons in the setting of antimicrobial use associated dysbiosis that manifest as DGBIs, most notably the constipation subtypes. This proposal will address whether antimicrobial use leads to quantitative and qualitative changes in the populations of submucosal neurons and glia cells in human subjects. This hypothesis will be tested in a prospective study in which healthy participants will be asked to take the commonly used antibiotic amoxicillin twice a day for 7 days, and colon tissue biopsies will be obtained before and after treatment. Human tissue will be processed and analyzed to visualize structural changes, and changes in gene expression, bacteria, metabolites will be determined through single nuclei RNA sequencing, 16S ribosomal bacteria RNA sequencing and metabolomics analysis respectively.

Interventions

DRUGAmoxicillin Oral Capsule

Amoxicillin 875mg every 12 hours for 7 days.

Sponsors

Rockefeller University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* 18-75 years old of different sex and races.

Exclusion criteria

* Allergy to penicillin, amoxicillin, augmentin, ampicillin, and other antibiotics in the penicillin family * Pregnancy or fertility treatments * Usage of antibiotics, antifungals or antivirals within three months prior to participation * Change in dietary habits within the last three months prior to participation such as transitioning from high fat western diet to primarily plant based diet, initiation of ketogenic, paleo or any other weight loss regimen. * Acute (in the past 30 days) or chronic enteric infections, including C. difficile. * Chronic gastrointestinal disorder including inflammatory bowel disease, celiac disease , irritable bowel syndrome, chronic constipation or diarrhea * Active neuropsychiatric disorder that requires anti-psychotic ie typical and atypical antipsychotics as well as anti-epileptics, levodopa, rivastigmine or any other neuropsychiatric medication with dopaminergic and cholinergic effects. * Myocardial infarction or cerebrovascular accident in the six months prior to participation * Coagulation disorders * Chronic immunosuppressive medication (systemic) usage * Anti-coagulation and anti-platelet agents such as plavix, warfarin, heparin, direct oral anticoagulants. * Low dose Aspirin does not constitute an

Design outcomes

Primary

MeasureTime frameDescription
Change in Mean Number of Colonic Submucosal Neurons/mm^2 in the Colon After Antibiotic Treatment7 daysChange in the mean number of colonic submucosal neurons counted per mm\^2 (+/- standard deviation) after antibiotics treatment compared to pre-treatment baseline.
Change in Mean Number of Colonic Submucosal Glia/mm^2 in the Colon After Treatment With Antibiotics7 daysChange in mean number of colonic submucosal glia counted per mm\^2 (+/- standard deviation) after antibiotics treatment compared to pretreatment baseline.

Secondary

MeasureTime frameDescription
Changes in Gene Expression in Submucosal Neurons7 daysNeurons nuclei will be isolated, and RNA will be sequenced and identified through alignment to human genome. The amount of RNA will be normalized as transcripts per million (TPM unit) and fold changes of a transcript will be calculated by dividing the TPM numbers of a transcript before and after antibiotics treatment.
Changes in Gene Expression in Submucosal Glia7 daysGlia nuclei will be isolated, and RNA will be sequenced and identified through alignment to human genome. The amount of RNA will be normalized as transcripts per million (TPM unit) and fold changes of a transcript will be calculated by dividing the TPM numbers of a transcript before and after antibiotics treatment.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORBegum Aydin, PhD

Rockefeller University

PRINCIPAL_INVESTIGATORYelina Alvarez, MD/PhD

Rockefeller University

Participant flow

Recruitment details

Healthy volunteers were recruited from the general public and the University's research volunteer repository. The first participant was screened on June 23, 2023 and accrual was completed on August 4 2023.

Pre-assignment details

There were no preassignment events of significance. Of the 10 participants consented, one withdrew from the study before the first study procedure.

Baseline characteristics

Characteristic
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
2 Participants
Age, Categorical
Between 18 and 65 years
7 Participants
Age, Continuous57 years
STANDARD_DEVIATION 11
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Mean number of colonic neurons counted / mm^2 (+/- standard deviation)0 cells/mm^2
STANDARD_DEVIATION 0
Mean number of glial cells counted/mm^2 (+/- standard deviation)661.39 cells/mm^2
STANDARD_DEVIATION 149.69
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
6 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
3 Participants
Region of Enrollment
United States
9 participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 10
other
Total, other adverse events
0 / 10
serious
Total, serious adverse events
0 / 10

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 13, 2026